The SWI/SNF chromatin-remodeling complex serves as a master switch that directs and limits the execution of specific cellular programs, such as differentiation and growth control. SWI/SNF function requires one of two paralogous ATPase subunits, Brahma (BRM) or BRMrelated gene 1 (BRG1), which we previously found are lost together in cancer cell lines and primary lung cancers. Although BRG1 has been found to be mutated in cancer cell lines, the mechanisms underlying BRM silencing are not known. To address this question, we sequenced BRM in 10 BRM/BRG1-deficient cancer cell lines and found that BRM was devoid of abrogating mutations. Moreover, histone deacetylase (HDAC) inhibitors restored BRM expression in each of these BRG1/BRM-deficient cancer cell lines, indicating that epigenetic silencing is a major mechanism underlying the loss of BRM expression. Despite their ability to restore BRM expression, these HDAC inhibitors also blocked BRM function when present. However, after their removal, we observed that BRM expression remained elevated for several days, and during this period, BRM activity was detected. We also found that the suppression of BRM occurs in a broad range of human tumor types and that loss of one or both BRM alleles potentiated tumor development in mice. Thus, BRG1 and BRM are silenced by different mechanisms, and it may be possible to clinically target and reexpress BRM in a number of tumor types, potentially impacting tumor development.
Introduction
The SWI/SNF chromatin-remodeling complex regulates gene expression by controlling access to the DNA through shifting the positions of histones within the chromatin. This complex is recruited to DNA by a variety of transcription factors and is required for the activity of a diverse number of important signaling pathways (Muchardt and Yaniv, 2001; KlochendlerYeivin et al., 2002) . The SWI/SNF complex's broad role in gene regulation is perhaps best demonstrated thus far in yeast, where its function is essential for regulation of at least 7% of genes (Sudarsanam et al., 2000) . SWI/ SNF contains one of two key ATPase subunits, either Brahma (BRM) or BRM-related gene 1 (BRG1) and 9-12 BRG1/BRM-associated factors (Wang et al., 1996) , which assemble into at least three different 2 MDa complexes. The SWI/SNF complex was first linked to tumorigenesis when the BAF47 subunit was found to be a bona fide tumor suppressor (Muchardt and Yaniv, 2001; Roberts and Orkin, 2004) . The loss of BAF47 expression has been shown to be a key event in the development of certain sarcomas, and homozygous deletion of this gene is highly tumorigenic in mice. We have subsequently found that the two catalytic SWI/ SNF subunits, BRG1 and BRM, are concomitantly lost in 30-40% of lung cancer cell lines (Reisman et al., , 2003 , as well as in 10-20% of primary lung cancers.
There are likely a number of mechanisms by which the loss of BRM promotes transformation. BRM was initially implicated in growth control mechanisms by the observation that exogenous BRM expression induces growth inhibition in BRM-deficient cell lines (Bourachot et al., 2003) . Explanted fibroblasts from BRM null mice demonstrate distinct abnormalities in cell-cycle control, further suggesting that the loss of BRM can perturb growth regulation (Coisy-Quivy et al., 2006) . Our research and that of others has shown that BRG1-and BRM-deficient cell lines are resistant to Rbmediated growth inhibition, and that reexpressing BRM in these cells is sufficient to restore Rb-mediated growth inhibition Strobeck et al., 2002) . The SWI/SNF complex and BRM are also required for differentiation and development (Simone, 2006) . Loss of BRM has also been shown to impact cell migration and metastasis (Yamamichi et al., 2005) . Given the potential importance of BRG1 and BRM loss in cancer development, we and others have sought to understand the mechanisms underlying how these proteins are silenced in cancer cells. BRG1 is commonly inactivated by mutations (Wong et al., 2000) , but the mechanism underlying BRM loss has not yet been elucidated. To understand how BRM is silenced in cancer cells, we sequenced BRM from 10 BRG1-and BRM-deficient cancer cell lines. We found that the BRM gene is not altered; but rather it is reversibly, epigenetically silenced and can be restored by treatment with histone deacetylase (HDAC) inhibitors. However, we found that HDAC inhibitors interfered with BRM function; but, after removal of HDAC inhibitors, BRM activity could be transiently restored. We further found that BRM loss was not restricted to lung cancer but present in a broad range of tumor types and that transgenic knockout of BRM potentiates lung tumor development in vivo. Together, our data show that BRM and BRG1 are lost in cancer cells through markedly different mechanisms.
Results
The BRM gene in BRG1/BRM-deficient cell lines is not mutated We and others have noted that BRG1 and BRM protein levels are consistently lost together in a variety of cancer cell lines (Muchardt and Yaniv, 2001; Reisman et al., 2002) . BRG1 has been found to be mutated (Wong et al., 2000) ) in these cell lines, but the various mechanisms that might underlie BRM loss have not been elucidated. To determine how BRM loss occurs, we analysed the BRM sequence in 10 cancer cell lines known to be deficient in both BRM and BRG1 expression. As gene silencing can result from insertions and deletions, nonsense mutations, or from defects in mRNA splicing, we sequenced BRM mRNA rather the genomic DNA from these cell lines. We did not detect nonsense mutations, insertions, deletions or splicing variants in the BRM mRNA from these cell lines. These results differ from analysis of BRG1, where we and others have found that BRG1 is silenced because of alterations and/or mutations in the gene (Wong et al., 2000 and data not shown). Moreover, we also sequenced each of the 34 BRM coding exons from three lung tumors that lacked BRM expression and also did not detect any mutations (data not shown). Thus, different mechanisms inhibited BRM and BRG1 expression in cancer cells. Furthermore, the observation that BRM sequence was not altered implied that reexpression of BRM in tumor cells might reconstitute BRM function.
Epigenetic silencing appears to underlie loss of BRM expression Given the apparent paucity of mutations in the BRM gene, we hypothesized that epigenetic silencing may be an important mechanism underlying the loss of BRM expression in these cancer cell lines. This notion is supported by the finding that HDAC inhibitors can restore BRM expression in some cell lines (Bourachot et al., 2003; Yamamichi et al., 2005) . To test this hypothesis, we treated our 10 cell lines that express very low or undetectable levels of BRM protein with butyrate, a broad-spectrum HDAC inhibitor. In each of these cell lines, butyrate treatment significantly upregulated BRM protein levels ( Figure 1a ). To determine if other known HDAC inhibitors can also restore BRM expression, we next examined the effects of several different HDAC inhibitors trichostatin A (TSA), MS-275 and CI-994 on BRM expression in the H522, SW13, A427 and H23 cell lines. We found that, like butyrate, TSA, MS-275 and CI-994 restored BRM expression (Figure 1b) . Thus, epigenetic silencing appears to be an important, if not the predominant, mechanism suppressing BRM expression. Furthermore, reexpression of BRM was not restricted to a specific compound or class of HDAC inhibitors, but rather was facilitated by a variety of different HDAC inhibitors.
Temporal effects of HDAC inhibitors on BRM reexpression
To characterize further the effect of HDAC inhibitors on BRM reexpression, we determined how BRM expression changes over time in butyrate-treated SW13 and H522 cells. Induction of BRM protein was detected at 12-24 h and reached a plateau between 24 and 48 h after addition of butyrate ( Figure 1c ). We next examined if BRM proteins levels would persist after butyrate removal. We observed that BRM protein remained elevated for 48 h and returned to near baseline levels at 96 h after withdrawal of butyrate from SW-13 cells (Figure 1d ), whereas in H522 cells, the BRM expression returned more slowly to its baseline at B120 h. We immunostained for BRM in both the SW13 and H522 cell lines at various time intervals after the removal of butyrate. BRM expression was detected in all cells immediately after withdrawal of butyrate; and BRM expression diminished equally throughout the population as a function of time after butyrate withdrawal (data not shown), indicating that loss of BRM expression after withdrawal of butyrate is not due to emergence of a minor subpopulation of BRM-deficient cells. Our data show that HDAC inhibitors rapidly induce BRM, but this effect is transient, because BRM expression returns to baseline within several days after butyrate removal.
Restoration of BRM function after treatment with HDAC inhibitors HDAC inhibitors are known to inhibit many of the 11 known HDACs -an effect that causes the acetylation and inhibition of a wide array of cellular proteins, including BRM (Bourachot et al., 2003) . An important clinical question arising from these observations is whether restoring BRM expression with these HDAC inhibitors reconstitutes BRM and SWI/SNF function. To address this question, we examined whether one or more of these other HDAC inhibitors can restore BRM function as well as expression in BRM-deficient cancer cell lines. To test for BRM function, we utilized the fact that steroid receptors, in particular the glucocorticoid receptor, are known to be functionally dependent on
The reversible epigenetic silencing of BRM S Glaros et al SWI/SNF activity (Muchardt and Yaniv, 1993; Trotter and Archer, 2004) . We used a subline of the BRG1/ BRM-deficient SW13 cell line, MG2-13, into which a glucocorticoid-responsive MMTV-luciferase (MMTVluc) reporter was stably introduced. The glucocorticoid dexamethasone cannot induce luciferase activity unless BRG1 function, and hence SWI/SNF complex activity, is restored in these cells (Trotter and Archer, 2004) . To determine whether, like BRG1, ectopic BRM expression can also induce luciferase activity, we introduced BRG1, BRM or their dominant-negative isoforms (dnBRG1 or dnBRM) (Khavari et al., 1993; Muchardt and Yaniv, 1993) into these reporter cells. Transient transfection of BRM but not dnBRM allowed dexamethasone to significantly induce luciferase activity (Figure 2a ), a finding in agreement with previous work by Muchardt and Yaniv (1993) and Bourachot et al. (2003) . Moreover, the induction of luciferase activity by BRM was comparable to that observed with BRG1. These findings indicate that either BRM-or BRG1-containing SWI/ SNF complexes can cooperate with glucocorticoid receptors. This observation is important because it supports the notion that BRG1 and BRM have some overlapping functions and that loss of both BRG1 and BRM may in some cases be required to inactivate certain signaling pathways.
We next examined whether induction of endogenous BRM by HDAC inhibitors could reconstitute the ability of the glucocorticoid receptor to induce luciferase activity. We treated MG2-13 with butyrate, then exposed the cells to dexamethasone for an additional 24 h and assayed for luciferase activity. Figure 2h) . We observed in these cell lines that each HDAC inhibitor significantly inhibited induction of luciferase activity (Figure 2c and d) .
To determine if these compounds directly affect BRM or other proteins necessary for luciferase activity, we utilized a previously described mutant form of BRM (BRM-K) in which specific residues in the C terminus have been changed (K-R) to prevent BRM acetylation and inactivation (Bourachot et al., 2003) . We introduced either BRM or BRM-K into MG2-13 cells and then treated with TSA or two clinically used HDAC inhibitors, MS275 and CI-994. In the BRM-transfected cells, dexamethasone induced luciferase activity only in the absence of these HDAC inhibitors (Figure 2e-g ). In contrast, in the BRM-K-transfected cells, we observed that dexamethasone induced luciferase activity in the presence of MS-275 and CI-994 and, to a lesser extent, with TSA (Figure 2e-g ). This induction was comparable to that seen in both BRM-and BRM-K-transfected MG2-13 cells without HDAC inhibitor treatment. These data specifically indicate that these HDAC inhibitors, although capable of inducing BRM expression, can block its function and thus are not ideal agents to target the restoration of BRM.
Because BRM expression persists for a period of days after removal of HDAC inhibitors (Figures 1d and 3a) , The reversible epigenetic silencing of BRM S Glaros et al we next examined if endogenous BRM function might be detectable after these compounds were removed. We observed that luciferase activity peaked 3 days after butyrate treatment and then tapered off in parallel with the reduction in BRM protein levels (Figure 3a) . This peak in luciferase activity occurred after the amount of acetylated BRM (inactive form) (Bourachot et al., 2003) diminished but before total BRM protein returned to baseline. We also observed a transient induction of luciferase activity several days after removal of CI-994, MS-275 and TSA (Figure 3b ). To determine if the observed induction of luciferase was due to BRM reexpression and not due to other possible HDAC inhibitor effects, we introduced either an empty vector or the dominant-negative form of BRM into MG2-13 cells after the removal of each HDAC inhibitor. These treated cells were then assayed for luciferase activity at the time when they showed peak luciferase activity. In (e-g) MG2-13 cells were transfected with either EV, BRM, or mutant form of BRM, BRM-K, as described previously (Bourachot et al., 2003) in which specific residues in the C terminus have been changed (K-R) that prevent BRM acetylation and inactivation. Cells were treated with either MS-275 (f), TSA (e) or CI994 (g) for 24 h, and then treated with either carrier or dexemathasone for an additional 24 h.
The reversible epigenetic silencing of BRM S Glaros et al each case, the dominant-negative BRM significantly reduced the luciferase activity as compared to control cells (Figure 3c and Supplementary data 3D). These data indicate that BRM is required for glucocorticoid receptor function and luciferase activity in the MG2-13 cells. Moreover, these data indicate that BRM function within BRM-deficient cells can be restored.
Reexpression of endogenous BRM by HDAC inhibitors restored CD44 expression
To confirm that endogenous BRM is functionally reconstituted by transient HDAC inhibitor exposure, we asked if these HDAC inhibitors could induce the expression of CD44, a BRM-dependent gene (Strobeck et al., 2001; Reisman et al., 2002) . CD44 expression was not detectable in butyrate-treated cells (Figure 4a ). However, after butyrate was removed, both CD44 mRNA and CD44 protein levels were induced and peaked 5 days after removal of butyrate (Figure 4a and b). We also observed induction of CD44 only after removal of TSA, MS-275 or CI-994 (Supplementary Figure 4e) . To show that this induction of CD44 was specifically due to BRM, we transfected butyrate-treated cells with either empty vector or the dnBRM and then measured CD44 expression. The induced levels of both CD44 mRNA and CD44 protein were blunted by dnBRM but not by the empty vector (Figure 4c and d). These data indicated that endogenous BRM, when induced, can restore SWI/SNF-dependent gene expression.
Loss of BRM expression potentiated tumor development
To determine if BRM loss in vivo can contribute to cancer development, we utilized the ethyl carbamate mouse model, which has been described previously (Tuveson and Jacks, 1999) . We bred heterozygous BRM mice to generate wild-type, heterozygous or null BRM mice (Figure 5a) . These mice were then treated with the lung-specific carcinogen ethyl carbamate at 8 weeks of age. The number of resultant lung adenomas in each group was monitored monthly, and when tumors began to develop in the control mice, 12 weeks post-treatment, Figure 3 (a) MG2-13 cells were exposed to butyrate for 72 h. Cells were then either treated during the last 24 h of this period (time point 0) or at subsequent intervals after butyrate removal with either carrier or dexamethasone for 24 h. After butyrate removal, levels of both the acetylated form of BRM (ac-BRM) and total BRM were examined by western blotting; GAPDH is the loading control. (b) MG2-13 cells were treated with TSA, MS-275 or CI-994 for 72 h and experiments were carried out as described in (a). Luciferase activity was measured in the present and at subsequent time intervals after removal of each of these HDAC inhibitors. (c) MG2-13 cells were treated with butyrate for 72 h, and then the butyrate was removed. These cells were then transfected with either EV or dnBRM and after 48 h were treated with dexamethasone or carrier for an additional 24 h.
The reversible epigenetic silencing of BRM S Glaros et al the mice in each group (N ¼ 10) were killed. The effects of BRM loss on tumor development were compared by counting the number of visible surface tumors. BRM wild-type mice had 2 or 3 adenomas per mouse, whereas BRM heterozygous and BRM null mice had B12 and B25 lung surface adenomas per mouse, respectively (Figure 5b) . Similarly, there was a notable increase in the number of adenomas seen in the cross-sectioned lungs of these animals. (Figure 5b and c) . This increase in tumorigenicity was not attributable to the concomitant loss of BRG1, because staining these mice for BRG1 revealed that BRG1 expression was retained in BRM knockout mice (data not shown). These data indicate that BRM loss potentiates lung tumor initiation and/or development.
BRM expression is lost in a variety of human cancers
We and others have observed that BRM expression is lost in lung cancer cell lines as well as in primary lung cancers (Reisman et al., 2003; Fukuoka et al., 2004) . The frequency of BRM loss in primary cancers other than lung has not yet been determined, although loss of BRM in a variety of cancer cell lines has been reported (Muchardt and Yaniv, 2001; Reisman et al., 2003) . We immunostained six different high-density, tissue-specific Figure 4 (a) MG2-13 cells were treated with butyrate for 72 h and then butyrate was removed. RNA and total proteins were harvested in the presence of butyrate and at various time points thereafter. GADPH is the loading control. (b) CD44 mRNA levels after butyrate removal were also measured by quantitative PCR and were standardized to GAPDH. (c and d) G2-13 cells were treated with butyrate as described in (a), transfected with either EV or dnBRM on day 3, and harvested for RNA and protein on day 5 after butyrate removal. On day 5, CD44 mRNA (d) as measured by quantitative PCR and CD44 protein levels measured by western blotting (c); GAPDH is the loading control. Quantitative PCR results for CD44 were standardized to GAPDH levels. The reversible epigenetic silencing of BRM S Glaros et al microarrays -lung, esophageal, ovarian, bladder, colon and breast carcinomas -using a BRM-specific polyclonal antibody. We found that for each tumor type examined, B15% of cases were devoid of BRM protein expression and B1-2% ( Figure 6 ) had weak or heterogeneous BRM expression (Table 1 and Figure 6 ). The BRM staining is nuclear as indicated by the solid black arrows in column a. In column c, the specific loss of nuclear staining is shown by gray arrows. In many of the tumors that lack BRM, internal positive controls, either infiltrating lymphocytes or bronchiolar epithelium, are seen staining positive for BRM (labeled with double black solid arrows). In column b, weak or faint BRM reactivity (hollow arrows) is observed in subsets of tumors: panels 1a, 2a, 4b and 6b. Other tumors have both positive-and negative-staining tumor cells intermixed (panels 3b and 5b).
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Discussion
We have previously reported that both BRG1 and BRM are often silenced together in cancer cell lines and in primary lung tumors (Reisman et al., 2003) . In BRG1/ BRM-deficient cell lines, BRG1 is commonly silenced by loss-of-function mutations. In contrast, no such mutations were detected for BRM in these cell lines. The observation that HDAC inhibitors induce BRM in each of the 10 cell lines examined indicates that epigenetic silencing is a predominant mechanism underlying BRM suppression. This reversible suppression of BRM in cancer cell lines also suggests that restoring BRM expression and BRM function in tumors is clinically feasible. Because SWI/SNF is functionally required for a variety of signaling pathways, it is very likely that many of these pathways are negatively impacted by the epigenetic suppression of BRM, and that reconstituting BRM function will restore key anticancer pathways. These findings make BRM an attractive target worth further investigation. Because BRM expression can be restored, determining the overall frequency of BRM expression loss in human cancer is a crucial step in assessing whether targeting BRM reexpression is an important priority for clinical treatment of cancer. The observation that BRM expression is silenced in about 15% of a variety of commonly occurring tumors types suggests that loss of BRM expression is likely involved in a significant number of human cancers.
The mechanism that accounts for BRM silencing is not known. Although HDAC inhibitors restore BRM expression, inappropriate HDAC activity may not be the mechanism underlying suppression of BRM. The regulation of gene expression by acetylation is known to depend on the balance between histone acetylase (HAT) and HDAC activity, as well as on the function of intermediate proteins such as transcription factors that recruit these chromatin-remodeling complexes to certain regions. Thus, BRM loss could occur because of specific losses of HAT, increases in HDAC activity or aberrant transcription factor activity.
Although restoring BRM expression may be a valuable clinical target in a number of tumor types, it is not clear yet which HDAC inhibitors, if any, may be ideally suited for this purpose. This is significant given that HDAC inhibitors are currently undergoing clinical trials and because these broad-spectrum agents have toxic side effects. We found that butyrate, TSA, CI-994 and MS-275 do not restore BRM function when present. This is in agreement with Bourachot et al. (2003) , who showed that butyrate induces the acetylation of BRM, rendering it inactive. Yet we also observed that after removing these compounds, BRM function was present, although transiently. Similarly, using MuLV virus gene expression as a marker, restoration of BRM function has been observed after removal of HDAC inhibitors (Yamamichi et al., 2005) . HDAC inhibitors were not identified because of their ability to inhibit specific HDACs, but rather uncovered in various drug screens because of their ability to reverse malignant phenotypes. The majority of known HDAC inhibitors are relatively nonspecific and inhibit many, if not most, of the 11 known HDACs. This lack of specificity likely underlies their toxicities. Thus, currently available compounds may not be ideally suited to target BRM, and newer compounds that specifically target only one or small subsets of the HDACs will likely be needed.
Materials and methods

Cell culture
Cell lines were grown in RPMI media supplemented with 5% fetal bovine serum and treated with TSA (Fisher Sci, Pittsburg, PA, USA) at 600 nM; MS-275 (Sigma) at 3 mM; butyrate (Sigma) at 5 mM; and CI-994 at 25 mM (Pfizer Pharmaceuticals, New York, NY, USA).
Western blotting and immunohistochemistry
All tissue microarray (TMAs) were constructed from University of Michigan surgical cases. 1:5000 dilution of antirabbit-GST-BRM was used (Machida et al., 2001) . Protein was extracted with 8 M urea, and analysed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anti-BRG1 (sc-17796, Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used at a dilution of 1:1000; and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Chemicon, Temecula, CA, USA) was used at 1:4000. BRM antisera were used at 1:1000. Antiacetylated BRM (Ac-BRM) antibody was used at 1:1000 (Bourachot et al., 2003) Luciferase assay MG2-13 (Trotter and Archer, 2004) were transfected with 3 mg of plasmid DNA using LipoFectamine 2000. Cell extracts were harvested using Passive Lysis Buffer (Promega, Madison, WI, USA). BRM-K was a gift from Christian Muchardt (Bourachot et al., 2003) . The rat glucocorticoid receptor and MMTV expression vectors were gift from Jorge A Iniguez-Lluhi University of Michigan. Firefly luciferase activity was measured in a Victor III plate reader and was standardized to total protein.
BRM mouse experiments
The BRM null mice were a gift from Moshe Yaniv. To generate lung tumors, ethyl carbamate (Sigma Cat. No. U2500) was administrated at 1 mg/kg weekly times 2 weeks.
